Latest news with #BCAX
Business Insider
5 days ago
- Business
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
In a report released on June 2, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), with a price target of $48.00. The company's shares closed yesterday at $11.01. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Willey covers the Healthcare sector, focusing on stocks such as Bicara Therapeutics Inc., Exelixis, and Abeona Therapeutics. According to TipRanks, Willey has an average return of 0.5% and a 37.45% success rate on recommended stocks. In addition to Stifel Nicolaus, Bicara Therapeutics Inc. also received a Buy from H.C. Wainwright's Robert Burns in a report issued yesterday. However, on May 23, Wells Fargo upgraded Bicara Therapeutics Inc. (NASDAQ: BCAX) to a Hold.
Yahoo
29-05-2025
- Business
- Yahoo
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update
On May 23, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (NASDAQ:BCAX) while keeping the price target at $36. This comes after the company released its interim data from Phase 1/1b trial of Ficerafusp alfa, which is the company's lead asset and a first-in-class bifunctional antibody. Close-up of a scientist in a lab conducting tests on a humanized immunoglobulin G1. Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company that develops innovative bifunctional antibody therapies for solid tumors. Ficerafusp alfa is being tested for enhanced tumor penetration and to overcome the immunosuppressive tumor microenvironment, which has historically limited treatment efficacy in solid tumors. The recent data from the Phase 1/1b study has shown promising results in treating HPV-negative patients who have head and neck squamous cell carcinoma. The analyst highlighted that the trial reported a median overall survival exceeding 20 months, including an 18-21% complete response rate. Frommer believes this is a significant improvement compared to standard care, suggesting that approval of Ficerafusp alfa could be a breakthrough in a challenging therapeutic area. While we acknowledge the potential of BCAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BCAX and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients
On May 24, analysts at Stifel reaffirmed their Buy rating and price target of $48 for Bicara Therapeutics Inc. (NASDAQ:BCAX). This follows the American Society of Clinical Oncology (ASCO) releasing abstracts after the market's close, which sparked debates regarding competing approaches to treating 1L SCCHN. The company's abstract provided a number of encouraging results for HPV-negative patients. These included an improved complete response (CR) rate, currently at 21%, a 12-month duration of response and overall survival (OS) of 60/61%, alongside a median overall survival (mOS) of more than 20 months. However, analysts pointed out that Merus, a market rival, also provided impressive full ASCO data that included both HPV-positive and HPV-negative patients. That said, Stifel analysts cautioned that it may be unreliable to draw competitive conclusions from non-randomized patient groups. In light of this, Stifel advises investors to purchase BCAX stock on any price weakness and to wait for more thorough information from Bicara at the next ASCO meetings. While we acknowledge the potential of BCAX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BCAX and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
23-05-2025
- Business
- Business Insider
Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp
The company states: 'Bicara Therapeutics (BCAX) announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line recurrent/metastatic head and neck squamous cell carcinoma on the 2025 American Society of Clinical Oncology Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset, including overall survival and duration of response data, following an oral presentation of the data at the ASCO Annual Meeting. Ficerafusp alfa is a first-in-class bifunctional antibody designed to enhance tumor penetration by breaking barriers within the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta.' 'We are pleased to present the fulsome dataset from our Phase 1/1b trial of ficerafusp alfa in patients with recurrent/metastatic head and neck squamous cell carcinoma during our upcoming oral presentation at ASCO,' said David Raben, MD, Chief Medical Officer of Bicara Therapeutics. 'The interim data featured in the ASCO abstract demonstrate encouraging signals that represent a meaningful improvement over historical benchmarks in patients with HPV-negative disease, a population with high unmet need and worse survival outcomes than those with HPV-positive disease. Notably, we're encouraged to see how ficerafusp alfa, specifically designed to drive tumor penetration within the tumor microenvironment, is leading to deep, and now, durable responses that appear to be translating to prolonged overall survival.'
Associated Press
25-03-2025
- Business
- Associated Press
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company's lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types. Details of the poster presentations are as follows: Title: Dose expansion results of single agent ficerafusp alfa (BCA101), a bifunctional EGFR/TGF-β inhibitor in patients with metastatic or advanced cutaneous squamous cell carcinoma (cSCC) Published Abstract #: CT034 Session Category: Clinical Trials Session Title: Phase 0 and Phase I Clinical Trials Session Date and Time: 4/28/2025 9:00 a.m. CT Location: McCormick Place Convention Center, Poster Section 49 This presentation will highlight data from a Phase 1/1b dose expansion cohort of ficerafusp alfa monotherapy in second line or later cSCC patients. Title: Dual blockade of EGFR and TGF-β with ficerafusp alfa has the potential to overcome resistance mechanisms in 1L R/M HNSCC in combination with Pembrolizumab Published Abstract #: 3284 Session Category: Clinical Research Session Title: Modifiers of the Tumor Microenvironment Session Date and Time: 4/28/2025 2:00 p.m. CT Location: McCormick Place Convention Center, Poster Section 30 This presentation will highlight a translational medicine biomarker dataset that provides insights into the effects of targeted inhibition of TGF-β with ficerafusp alfa. Title: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lung tumors Published Abstract #: 4434 Session Category: Experimental and Molecular Therapies Session Title: Reversal of Drug Resistance Session Date and Time: 4/29/2025 9:00 a.m. CT Location: McCormick Place Convention Center, Poster Section 23 This presentation will highlight a preclinical dataset that provides insights into the role of inhibiting TGF-β in overcoming acquired KRAS-G12C-inhibitor drug-resistant KRAS-G12C-mutated lung cancer. Following the meeting, the poster presentations will be available on Bicara's website at About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara's lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Bicara's preclinical studies and presentation of results, the clinical development of ficerafusp alfa and presentation of data from a Phase 1/1b dose expansion cohort of ficerafusp alfa monotherapy in second line or later cSCC, clinical development of ficerafusp alfa in combination with pembrolizumab, the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy and tolerability. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct and enrollment of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials and regulatory developments in the United States and foreign countries, whether Bicara's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara's filings with the Securities and Exchange Commission (SEC), including Bicara's Quarterly Report on Form 10-Q for the period ended September 30, 2024, as well as any subsequent filings that Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara's views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contacts Investors Rachel Frank Media Dan Budwick 1AB
